ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Conditions: Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Metastatic Prostate Small Cell Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8 Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694; Drug: Enzalutamide; Biological: Pembrolizumab Sponsors: Rahul Aggarwal; Zenith Epigenetics; Merck Sharp & Dohme Corp.; U.S. Army Medical Research and Development Command Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials